Researchers identify high rates of untreated hypertension in young veterans

https://www.news-medical.net/news/20260422/Researchers-identify-high-rates-of-untreated-hypertension-in-young-veterans.aspx Approximately half a million post-9/11 U.S. veterans who served in the military have had high blood pressure, and among them, about half were undiagnosed and one quarter were untreated, according to a new study published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

How Indoor Air Quality and Building Design Shape Human Health

https://www.news-medical.net/health/How-Indoor-Air-Quality-and-Building-Design-Shape-Human-Health.aspx From green spaces to indoor air and plumbing systems, the urban microbiome may help explain how city design influences immune health, respiratory risk, and the future of healthier buildings.

Antibiotic Resistance vs. Antibiotic Tolerance: What is the Difference?

https://www.news-medical.net/health/Antibiotic-Resistance-vs-Antibiotic-Tolerance-What-is-the-Difference.aspx Antibiotic resistance allows bacteria to grow despite antibiotic exposure, whereas antibiotic tolerance allows them to survive lethal treatment longer without increasing MIC. Understanding this distinction helps explain treatment failure, relapse, and the need for better diagnostics beyond standard susceptibility testing.

Autism risk rises with multiple medications taken during pregnancy

https://www.news-medical.net/news/20260422/Autism-risk-rises-with-multiple-medications-taken-during-pregnancy.aspx Widely prescribed medications that disrupt cholesterol synthesis may be linked to increased autism diagnoses in children. This prompts new scrutiny of drug safety during pregnancy and the need for more cautious prescribing. A recent Molecular Psychiatry study examined the association between maternal prescription of sterol biosynthesis inhibiting medications (SBIMs) during pregnancy and the subsequent risk of autism spectrum disorders (ASD) in offspring, utilizing a large, linked maternal-child health record database.

Editorial Diagnostics and therapeutics: the CRISPR story continues The Lancet Microbe +++ +...

Safety, recovery, and pharmacodynamics of CRISPR–Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study Anders Østergaard Petersen, PhDa ∙ Birgitte Damholt, PhDa ∙ Mette Grove, PhDa ∙ Jonas Hink, PhDa ∙ Tamara Marotte-Hurbon, MSca ∙ Johan Söderqvist, MSca ∙ et al. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00185-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanmic&utm_campaign=update-lanmic&utm_medium=email&_hsenc=p2ANqtz-9BtKlzOmT-8aVyPJkIoM-dxwbV6Gh0SSs8sVZt38ILMIvSB_ULBehzdASlcts_7p-Q9HrHEXBu-LITmHpjxrPYYBca4Q&_hsmi=414946141&utm_content=414664356&utm_source=hs_email Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study Hans de Graaf, PhDa,b,c,d,∗ ∙ Diane F Gbesemete, PhDa,b,e,∗ ∙ Alison R Hill, PhDa,b,e,∗ ∙ Janeri Fröberg, PhDc,d ∙ Muktar M Ibrahim, PhDe ∙ Adam P Dale, PhDa,b,e ∙ et al. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00241-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanmic&utm_campaign=update-lanmic&utm_medium=email&_hsenc=p2ANqtz-99dyMyxjhTJfb5i_TU7ROzf9mVTqtKS9kNSSOUKyJT4ujuPoLPdKPYFwAUwLm2lOt28O6tm22QTEuCTarKosooMV77zA&_hsmi=414946141&utm_content=414664356&utm_source=hs_email Lineage dynamics of invasive Escherichia coli isolates in the Netherlands from 1975 to 2021: a retrospective longitudinal genomic analysis Ann E Snaith, PhDa,∗ ∙ Boas van der Putten, PhDb,c,∗ ∙ Wendy Bril-Keijzers, BScb ∙ Rebecca J Hall, PhDa ∙ Steven J Dunn, PhDa ∙ Prof Willem van Schaik, PhDa ∙ et al. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00228-9/fulltext?dgcid=hubspot_update_feature_updatealerts_lanmic&utm_campaign=update-lanmic&utm_medium=email&_hsenc=p2ANqtz-91tusPdEbxZGWXU6-SuIgwv5nq3muzvHfF0iH6yPaoJyKgYSC1k5tEbkjl5RdM7E8JkFMcLSsGv2P2audbbeRrHRH-nA&_hsmi=414946141&utm_content=414664356&utm_source=hs_email Editorial Diagnostics and therapeutics: the CRISPR story continues The Lancet Microbe https://www.thelancet.com/journals/lanmic/issue/vol7no4/PIIS2666-5247(26)X2003-1

BMI-based barriers to joint replacement in the UK The Lancet Rheumatology ++... ++

BMI-based barriers to joint replacement in the UK The Lancet Rheumatology https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00116-5/fulltext?dgcid=raven_jbs_etoc_email May 2026 Volume 8Number 5e321-e406 https://www.thelancet.com/journals/lanrhe/issue/vol8no5/PIIS2665-9913(26)X2004-5 A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial Anusha Moses, MSca Send email to anusha.moses93@icloud.com ∙ Martijn A H Oude Voshaar, PhDa,b ∙ Eva H van Geel, MDc ∙ Lydia Schipper, PhDd ∙ Iris Rose Peeters, MSce ∙ Reinhard Bos, MDf ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00034-2/abstract?dgcid=raven_jbs_etoc_feature_lanrhe Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab Prof Athimalaipet V Ramanan, FMedScia Send email to a.ramanan@bristol.ac.uk ∙ Prof Nicolino Ruperto, MDb ∙ Ivan Foeldvari, MDc ∙ Gabriel Vega-Cornejo, MDd ∙ Stuart Keller, BSce ∙ Rona Wang, MDe ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00346-7/abstract?dgcid=raven_jbs_etoc_feature_lanrhe

CLINICAL PERSPECTIVES +++ ++++ (videos)

CLINICAL PERSPECTIVES FDA’s Plausible Mechanism Framework and its Effect on Rare Disease Therapy Development https://checkrare.com/fdas-plausible-mechanism-framework-and-its-effect-on-rare-disease-therapy-development/ Stevie Ringel, CEO of Nome Therapeutics, discusses the US Food and Drug Administration’s (FDA) Plausible Mechanism Framework and its effect on rare disease therapy development. Nipocalimab Granted Fast Track Designation in Systemic Lupus Erythematosus https://checkrare.com/nipocalimab-granted-fast-track-designation-in-systemic-lupus-erythematosus/ Richard A. Furie, MD, Chief of the Division of Rheumatology at Northwell Health, discusses nipocalimab for the treatment of systemic lupus erythematosus (SLE). Accelerated Approval of Yuviwel (Navepegritide) for Patients with Achondroplasia https://checkrare.com/accelerated-approval-of-yuviwel-navepegritide-for-patients-with-achondroplasia/ Carlos A. Bacino, MD, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital, discusses the accelerated approval of Yuviwel (navepegritide) for patients with achondroplasia. MESA Extension Study of Sevasemten in Patients With Becker Muscular Dystrophy https://checkrare.com/mesa-extension-study-of-sevasemten-in-patients-with-becker-muscular-dystrophy/ Joanne Donavan, MD, PhD, Chief Medical Officer at Edgewise Therapeutics, discusses the MESA extension study of sevasemten for the treatment of patients with Becker muscular dystrophy (BMD). How The FDA’s Plausible Mechanism Framework Is Accelerating Approval for Osteosarcoma Immunotherapy https://checkrare.com/how-the-fdas-plausible-mechanism-framework-is-accelerating-approval-for-osteosarcoma-immunotherapy/ Paul Romness, CEO of OS Therapies, discusses the Plausible Mechanism Framework draft guidance and how it will affect the approval process of OST-HER2 LM for the treatment of osteosarcoma. First Patient Dosed in FALCON Clinical Trial Evaluating SGT-212 Gene Therapy for Friedreich’s Ataxia https://checkrare.com/first-patient-dosed-in-falcon-clinical-trial-evaluating-sgt-212-gene-therapy-for-friedreichs-ataxia/ Gabriel Brooks, MD, Chief Medical Officer at Solid Biosciences, and Russell Lonser, MD, of The Ohio State University Wexner Medical Center, discuss SGT-212 and the FALCON clinical trial for patients with Friedreich’s ataxia. Phase 1/2 Results of Tividenofusp Alfa in Patients With MPS II https://checkrare.com/phase-1-2-results-of-tividenofusp-alfa-in-patients-with-mps-ii/ Joseph Muenzer, MD, PhD, Pediatric Biochemical Geneticist at University of North Carolina Chapel Hill, discusses results from a phase 1/2 study of tividenofusp alfa in patients with mucopolysaccharidosis II (MPS II).